AI assistant
Vaxcyte, Inc. — Director's Dealing 2024
Jul 2, 2024
31100_dirs_2024-07-02_c2bf2a60-6640-4219-86a7-fced65445f6e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-07-01
Reporting Person: Wassil Jim (CHIEF OPERATING OFFICER)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-07-01 | Common Stock | S | 1226 | $75.7548 | Disposed | 212277 | Direct |
| 2024-07-01 | Common Stock | S | 1663 | $76.7086 | Disposed | 210614 | Direct |
| 2024-07-01 | Common Stock | S | 111 | $77.215 | Disposed | 210503 | Direct |
Footnotes
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023.
F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $75.21 to $76.20. The reporting person will provide upon request to the SEC, the issuer or security holder of
the issuer, full information regarding the number of shares sold at each separate price.
F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $76.21 to $77.14. The reporting person will provide upon request to the SEC, the issuer or security holder of
the issuer, full information regarding the number of shares sold at each separate price.